Mainz Biomed B.V.

NasdaqCM MYNZ

Mainz Biomed B.V. Price to Sales Ratio (P/S) on January 14, 2025: 13.12

Mainz Biomed B.V. Price to Sales Ratio (P/S) is 13.12 on January 14, 2025, a 397.30% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Mainz Biomed B.V. 52-week high Price to Sales Ratio (P/S) is 17.82 on December 02, 2024, which is 35.82% above the current Price to Sales Ratio (P/S).
Mainz Biomed B.V. 52-week low Price to Sales Ratio (P/S) is 0.39 on November 25, 2024, which is -97.06% below the current Price to Sales Ratio (P/S).
Mainz Biomed B.V. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.70.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: MYNZ

Mainz Biomed B.V.

CEO	Mr. Guido Baechler
IPO Date	Nov. 5, 2021
Location	Germany
Headquarters	Robert Koch Strasse 50
Employees	65
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Key trends

Past 5 years